COVID-19 represents an unprecedented public health crisis that will bring many novel insights. This worldwide disturbance will probably affect the epidemiology of antimicrobial resistance (AMR) in many different ways that we have not previously considered.
We need to rethink the antibiotic discovery paradigm. Killing bacteria directly is one strategy with which we are very familiar, but it is not the only way forward. Read more in a new perspective by Professor Bob Hancock.
The spectre of an infectious disease pandemic killing tens of thousands of people across the globe is no longer a theoretical nightmare scenario. The World Health Organization’s ‘Disease X’ is here and despite consistent efforts by WHO and others to keep the political focus on this threat, the world has been caught largely unprepared.
There is a growing awareness that companies with newly approved antibiotics face substantial economic challenges. Yet we remain concerned that there is a general lack of understanding of the mechanics driving the collapse of the industry. Understanding the root causes and identifying which are addressable through alternate strategies or changes in behaviors vs. those that are a fundamental feature of the antibacterial marketplace is critical to finding lasting solutions.
Gonorrhoea and chlamydia are the two most common sexually transmitted infections in the world. Their similar symptoms make it challenging to differentiate between the infections and treat appropriately. As a consequence, syndromic treatment of gonorrhoea leads to inappropriate use of antibiotics. Cassandra Kelly-Cirino and Cecilia Ferreyra from FIND discuss why new and better diagnostics are needed to safeguard drugs to treat gonorrhoea.